3rd Quarter Financial Results for
FYE/Mar. 2007
Results Overview and Topics

Terumo Corporation
1

Sales and profits continuing to enjoy(Unit: billion yen)double-digit growth
3Q FYE/Mar. 2006

3Q FYE/Mar. 2007

Net Sales

183.6

205.1

Gross Profit (%)

100.1 (54.5%) 113.2 (55.2%) 13.1%

SGA Expenses (%)

61.4 (33.4%)

68.0 (33.2%) 10.7%

Operating Income (%)

38.7 (21.1%)

45.2 (22.0%) 16.9%

Ordinary Income (%)

39.3 (21.4%)

46.3 (22.5%) 17.7%

Net Income (%)

25.0 (13.6%)

29.5 (14.4%) 18.0%

Averageexchange rate

US$EUR

112 yen
137 yen

116 yen
148 yenRate of change

11.7%

3.6% yen depreciation
8.1% yen depreciation
2

Net Sales (by product group)(Unit: billion yen)

205.1

+21.6

183.6
33.7
28.5

36.6
21.3

+5.2

Consolidated total: 11.7%

CV and vascular grafts(Growth rate: 18.3%)

46.5

+9.9

Interventional products(Growth rate: 27.0%)

21.9+0.5

Home health care products(Growth rate: 2.6%)

+5.9

97.2

103.1

3Q FYE/Mar. 2006

3Q FYE/Mar. 2007

General hospital products(Growth rate: 6.1%)

3

Net Sales (by Region)(Unit: billion yen)

Consolidated Net Sales

205.1+21.6

11.7% (9.5%)

1 7 .1+2.5

Asia&Others 16.8% (11.1% )1 4 .6
2 8 .5

3 8 .0+9.5

2 8 .23 4 .8+6.6

183.6

1 1 2 .3

3Q FYE/Mar. 2006

1 1 5 .3+3.0

3Q FYE/Mar. 2007

Overseas sales ratio (%)
39%
44%Americas

33.4% (29.8% )Europe3.3% (15.2% )Overseas26.0% (20.2%)

Japan

2.7%
Excluding impact offoreign exchange

4Gross Profit Margin: 55.2% +0.7pt
compared to previous year
Negative factors : ▲0.9pt

Positive factors : +1.6pt

Shift to higher-profit

Effect of production
increase

Price decline, etc.

+0.1

products▲0.9+1.5+0.7pt
5Details of SGA Expenses(Unit: billion yen)

68.0+6.6

11.6+0.5

R&D+0.7+0.3

Sales promotion andadvertising (11.6%)(Increase rate)

61.4
11.1
6.9
6.2

5.7

5.4

Logistics
23.6

20.7+3.0

3Q FYE/Mar. 2006

20.1(6.3%)

Personnel (14.4%)
Others18.1(4.4%)(11.3%)+2.0

3Q FYE/Mar. 2007

SGA Expenses rate
33.4%
33.2%

▲0.2pt6Expecting to Achieve the Forecast
for Full Fiscal Year
(Unit: billion yen)
FYE/Mar. 2006

Increase
FYE/Mar. 2007 (forecast) rate

Net Sales

247.0

273.0

11%

Operating Income (%)

48.3 (19.5%)

57.5 (21.1%)

19%

Ordinary Income (%)

48.9 (19.8%)

57.5 (21.1%)

18%

Net Income (%)

32.5 (13.1%)

37.0 (13.6%)

14%

US$ 113 yen
EUR 138 yen

US$ 116 yen
EUR 148 yen

Exchange rate
for the year7

Topics8

DuraHeart

Latest clinical trial data(as of January 25, 2007)

Mean age (Average)

54.5

Mean duration of support (days)

165

No. of patients supported > 6 months（> 12 months）

11（4）Overall survival (%)

76

Mean days of hospitalisation (days)

45

9DuraHeart

Differences identified
in long-term survival

Comparison by the Kaplan-Meier Survival Analysis
(%)

100
90
80
70
60
5040DH (N=29)

Comparison group (N=655)

Comparison group: LVAD registry, the Transplant Society

70%
Early stage deaths mainly
depend on difference inpatients

03

650%

912Survival rates
change inlong-term
implanting

1518（months）
10

DuraHeart

Left ventricular assist system"DuraHeart"■Europe: CE Mark expected in the 4th quarter thisfiscal year
■U.S.

: Application for clinical trial planned in thenext fiscal year

■Japan : Preparation in progress for application forclinical trial

11

Drug-eluting stent"Nobori"■Europe: CE Mark expected in 4th quarter thisfiscal year
■Japan : Preparation in progress, applicationfor clinical trial■Implant of 360 cases completed12

Sales in Japan now in recovery
Growthrate

Comparison with the same periodof the previous year (growth rate)

Comparisonby quarter

7.0%
6.0%
5.0%
4.0%
3.0%
2.0%
1.0%
0.0%
-1.0%
-2.0%

1Q FYE Mar.
2007

2Q FYE Mar.
2007

3Q FYE Mar.
2007

13

Pharmaceuticals drive
the business in Japan¾ I.V. solution- Standardization and streamlining of products
in progress, expanding sales- Good sales of new product with superb
risk management functions, "Amigrand""Amigrand”¾ Pre-filled syringes- Minofit sales gradually increasing- Good sales of contrast media continuing"Minofit"
Syringe for liver disease and allergies
14

Sales of diabetes care products
continue to grow
¾ Device for glucose monitoring,"Medisafe Mini"- 22% share in Japan- Focusing on safety and convenience"Medisafe Mini"¾ Insulin needles, "NanoPass"- Domestic sales gradually increasing- Production capability to be increased in future
Reduce pain needle"NanoPass"
15

Joint Venture with Olympus¾ Terumo's collagen business joining forces with Olympus'
biomaterial and regenerative medicine business"Olympus Terumo Biomaterial Corp."(Established on April 1, 2007)¾Development of new composite artificial
bone substitute material• Application to treatment of bonediseases (fractures and bone tumors)• Creating new markets for minimallyinvasive therapies by developing
patient-friendly biomaterials

Ceramics element

Composite artificial bone
CollagenNew composite bone substitutematerial image¾Securing a foothold for the enteringorthopedics market

16IR Contact
TERUMO Corporation
Corporate Communication (IR) Dept.
E-mail: Kazuya_Haraguchi@terumo.co.jp
This document contains forward-looking statements that reflect
management’s current views with respect to certain future events andfinancial performance. Actual results may differ materially from thoseprojected or implied in the forward-looking statements and from historical
trends. Furthermore, certain forward-looking statements are based uponassumptions of future events that may not prove to be accurate. Factorsthat could cause actual results to differ materially from those projected or
implied in any forward-looking statements include, but are not limited to,changes in overall economic conditions, fluctuations of foreign exchange
rates, and intensifying price competition in the markets for our products.
17